great result from biotron, page-8

Your right about derisking. This was a significant hurdle that BIT could have fell over on being a first in class concept. The safety of the compound was proved in the previous trial and this trial needed to show some positive efficacy on its own. It has done that and since :

" "We know from previous preclinical studies that BIT225’s
potency is significantly enhanced in combination with interferon-alpha and ribavirin, so we would expect greater efficacy levels in future combination studies" said Dr Michelle Miller"

we would expect that the parties that BIT has alluded to being interested in partnering would be very interested at this point.